EE9800257A - Sünteetilised HIV geenid - Google Patents

Sünteetilised HIV geenid

Info

Publication number
EE9800257A
EE9800257A EE9800257A EE9800257A EE9800257A EE 9800257 A EE9800257 A EE 9800257A EE 9800257 A EE9800257 A EE 9800257A EE 9800257 A EE9800257 A EE 9800257A EE 9800257 A EE9800257 A EE 9800257A
Authority
EE
Estonia
Prior art keywords
synthetic hiv
hiv genes
genes
synthetic
hiv
Prior art date
Application number
EE9800257A
Other languages
English (en)
Estonian (et)
Inventor
W. Shiver John
M. Davies Mary-Ellen
C. Freed Daniel
A. Liu Margaret
C. Perry Helen
Original Assignee
Merck & Co., Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9607293.9A external-priority patent/GB9607293D0/en
Application filed by Merck & Co., Inc. filed Critical Merck & Co., Inc.
Publication of EE9800257A publication Critical patent/EE9800257A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EE9800257A 1996-02-22 1997-02-18 Sünteetilised HIV geenid EE9800257A (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1208296P 1996-02-22 1996-02-22
GBGB9607293.9A GB9607293D0 (en) 1996-04-09 1996-04-09 Synthetic hiv env genes
PCT/US1997/002294 WO1997031115A2 (en) 1996-02-22 1997-02-18 Synthetic hiv genes

Publications (1)

Publication Number Publication Date
EE9800257A true EE9800257A (et) 1999-02-15

Family

ID=26309076

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9800257A EE9800257A (et) 1996-02-22 1997-02-18 Sünteetilised HIV geenid

Country Status (27)

Country Link
EP (1) EP0904380B1 (ko)
JP (1) JP2000505299A (ko)
KR (1) KR19990087126A (ko)
CN (1) CN1216064A (ko)
AR (1) AR005930A1 (ko)
AT (1) ATE309366T1 (ko)
AU (1) AU729231B2 (ko)
BG (1) BG102784A (ko)
BR (1) BR9707672A (ko)
CO (1) CO4600706A1 (ko)
CZ (1) CZ266798A3 (ko)
DE (1) DE69734585T2 (ko)
EE (1) EE9800257A (ko)
ES (1) ES2251734T3 (ko)
HR (1) HRP970092A2 (ko)
HU (1) HUP9901112A3 (ko)
ID (1) ID16021A (ko)
IL (1) IL125547A0 (ko)
IS (1) IS4814A (ko)
NO (1) NO983876L (ko)
NZ (1) NZ331161A (ko)
PE (1) PE43298A1 (ko)
PL (1) PL328730A1 (ko)
SK (1) SK112998A3 (ko)
TR (1) TR199801615T2 (ko)
WO (1) WO1997031115A2 (ko)
YU (1) YU35498A (ko)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6534312B1 (en) 1996-02-22 2003-03-18 Merck & Co., Inc. Vaccines comprising synthetic genes
CA2258568A1 (en) * 1996-06-21 1997-12-24 Merck & Co., Inc. Vaccines comprising synthetic genes
US6696291B2 (en) 1997-02-07 2004-02-24 Merck & Co., Inc. Synthetic HIV gag genes
IL131131A0 (en) * 1997-02-07 2001-01-28 Merck & Co Inc Synthetic hiv gag genes
NZ338093A (en) 1997-04-04 2001-06-29 Patricia L Herman Methods and materials for making and using transgenic dicamba-degrading organisms
US7105724B2 (en) 1997-04-04 2006-09-12 Board Of Regents Of University Of Nebraska Methods and materials for making and using transgenic dicamba-degrading organisms
OA11520A (en) * 1997-10-20 2004-02-09 Genzyme Transgenics Corp Novel modified MSP-1 nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems.
AU2003200914B2 (en) * 1997-10-20 2007-02-01 Gtc Biotherapeutics, Inc. Novel modified nucleic acid sequences and methods for increasing mRNA levels and protein expression in cell systems
GB9803351D0 (en) 1998-02-17 1998-04-15 Oxford Biomedica Ltd Anti-viral vectors
US6924365B1 (en) 1998-09-29 2005-08-02 Transkaryotic Therapies, Inc. Optimized messenger RNA
EP1535995A1 (en) * 1998-12-31 2005-06-01 Chiron Corporation Polynucleotides encoding the antigenic HIV type C env polypeptide and uses thereof
EP1433851A3 (en) * 1998-12-31 2004-10-13 Chiron Corporation Improved expression of HIV polypeptides and production of virus-like particles
CA2360347C (en) * 1998-12-31 2013-05-07 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
JP2003523721A (ja) 1998-12-31 2003-08-12 カイロン コーポレイション 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用
US6395714B1 (en) 1999-02-24 2002-05-28 Aventis Pasteur Limited Expressing gp140 fragment of primary HIV-1 isolate
CA2369119A1 (en) 1999-03-29 2000-05-25 Statens Serum Institut Nucleotide construct with optimised codons for an hiv genetic vaccine based on a primary, early hiv isolate and synthetic envelope
US8647864B2 (en) 1999-04-14 2014-02-11 Novartis Ag Compositions and methods for generating an immune response utilizing alphavirus-based vector systems
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE COMPRISING A GAG GENE VEHICLE ADENOVIRUS
EP2278022A3 (en) 1999-11-01 2011-05-18 Novartis Vaccines and Diagnostics, Inc. Expression vectors, transfection systems, and method of use thereof
WO2001045748A1 (en) * 1999-12-22 2001-06-28 Merck & Co., Inc. Polynucleotide vaccines expressing codon optimized hiv-1 pol and modified hiv-1 pol
GB0014288D0 (en) 2000-06-10 2000-08-02 Smithkline Beecham Biolog Vaccine
GB0017990D0 (en) 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
US6733994B2 (en) * 2000-10-04 2004-05-11 The Trustees Of The University Of Pennsylvania Highly expressible genes
KR20020059856A (ko) * 2001-01-08 2002-07-16 김철중 에이치아이브이 유사입자의 제조
US7211659B2 (en) 2001-07-05 2007-05-01 Chiron Corporation Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof
EP1427826B1 (en) * 2001-09-20 2011-04-20 Glaxo Group Limited HIV- RT-nef-Gag codon optimised DNA vaccines
WO2005063286A1 (en) 2003-12-23 2005-07-14 Arbor Vita Corporation Antibodies for oncogenic strains of hpv and methods of their use
US7855326B2 (en) 2006-06-06 2010-12-21 Monsanto Technology Llc Methods for weed control using plants having dicamba-degrading enzymatic activity
US8754011B2 (en) 2006-10-16 2014-06-17 Monsanto Technology Llc Methods and compositions for improving plant health
US7838729B2 (en) 2007-02-26 2010-11-23 Monsanto Technology Llc Chloroplast transit peptides for efficient targeting of DMO and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ262582A (en) * 1993-01-26 1997-10-24 David B Weiner Compositions and methods for delivery of genetic material
DE69536091D1 (de) * 1994-01-27 2010-09-09 Univ Massachusetts Medical Immunisierung durch Impfung von DNS Transkriptionseinheit
US6630455B1 (en) * 1995-01-13 2003-10-07 Vanderbilt University Methods for inducing mucosal immune responses
JPH08198774A (ja) * 1995-01-20 1996-08-06 Terumo Corp Ｄｎａワクチン

Also Published As

Publication number Publication date
YU35498A (sh) 1999-07-28
TR199801615T2 (xx) 1998-11-23
EP0904380A2 (en) 1999-03-31
PL328730A1 (en) 1999-02-15
EP0904380B1 (en) 2005-11-09
BR9707672A (pt) 1999-04-13
PE43298A1 (es) 1998-08-29
NO983876L (no) 1998-10-21
DE69734585T2 (de) 2006-08-10
CZ266798A3 (cs) 1999-03-17
CN1216064A (zh) 1999-05-05
BG102784A (en) 1999-05-31
AU2124697A (en) 1997-09-10
HUP9901112A2 (hu) 1999-07-28
ATE309366T1 (de) 2005-11-15
KR19990087126A (ko) 1999-12-15
CO4600706A1 (es) 1998-05-08
HRP970092A2 (en) 1998-04-30
AU729231B2 (en) 2001-01-25
IS4814A (is) 1998-07-30
ES2251734T3 (es) 2006-05-01
WO1997031115A3 (en) 1997-10-09
AR005930A1 (es) 1999-07-21
NO983876D0 (no) 1998-08-21
HUP9901112A3 (en) 2001-06-28
NZ331161A (en) 2000-03-27
ID16021A (id) 1997-08-28
JP2000505299A (ja) 2000-05-09
DE69734585D1 (de) 2005-12-15
WO1997031115A2 (en) 1997-08-28
IL125547A0 (en) 1999-03-12
SK112998A3 (en) 2000-04-10

Similar Documents

Publication Publication Date Title
ID16021A (id) Gen-gen hiv sintetis
NO975305L (no) Hydroksyfenyltriaziner
ATE208395T1 (de) Thiophenopyrimidine
ATE262512T1 (de) Arylalkanoylpyridazine
ATE208773T1 (de) Chinoxalindione
NO996435D0 (no) Polymerisasjonsprosess
ATE353652T1 (de) Östroprogestatives antikonzeptionsmittel
DE59709322D1 (de) Ferrocenderivate
NO20003168L (no) Polymerisasjonsmetode
DE59810608D1 (de) Stapelvorrichtung
DE69718354D1 (de) Papierklammer
ID16421A (id) Gen-gen sintetik
NO993432D0 (no) Polymerisasjonsprosess
ID16013A (id) PEROLEHAN ε-KAPROLAKTAM
DE69835157D1 (de) Reihenelektroden-anodisierung
NO961015D0 (no) Fristempelgassgenerator
FR2770103B1 (fr) Bigoudi perfectionne
SE9601422D0 (sv) Synthetic genes
SE9603469D0 (sv) Synthetic genes
FI100512B (fi) Lehtiötaulu
NO996436D0 (no) Polymerisasjonskatalysator
FI2369U1 (fi) Sarjalomake
KR970051149U (ko) 여러가지 돌아이바이
BR9600867A (pt) Conjunto empacotadora-enfardadora
SE9600402D0 (sv) Hållaranordning